Explorez tous les épisodes du podcast Eagle's Eye View: Your Weekly CV Update From ACC.org
| Titre | Date | Durée | |
|---|---|---|---|
| SPECIAL TCT RECAP focusing on four studies: PROGRESS on TAVR & AS; SIMPLAFFY on NOACS & DAPT; SPYRAL AFFIRM on RDN & BP; IRIS MAIN on PCI & CABG | 05 Nov 2026 | 00:10:13 | |
In this special edition of the View, Dr. Eagle looks at four studies presented at the recent TCT Conference that could have immediate effects on your practice. First, he discusses PROGRESS, that investigated how TAVR may be superior to clinical surveillance in patients with moderate aortic stenosis (AS) with at-risk features. He then examined SIMPLAAFY, that explored how the use of reduced-dose non-vitamin K oral anticoagulants (NOACs) was noninferior to dual antiplatelet therapy (DAPT) for a composite of adverse clinical outcomes through six months following left atrial appendage closure (LAAC). He then takes a look at SPYRAL AFFIRM, on the effectiveness of radiofrequency RDN on blood pressure (BP) at six months. Finally, Dr. Eagle offers a summary of a non-randomized analysis of the IRIS-MAIN registry that indicated no statistically significant difference in long-term all-cause mortality among Asian patients with unprotected left main coronary artery disease (CAD) who underwent PCI or CABG. Get ACC's full coverage of the TCT conference here. | |||
| Underdiagnosis of AFib in Black Adults; Echocardiographic Evaluation; CAC Scores in Young Adults; Add-On Treatments For Resistant Hypertension | 04 Nov 2026 | 00:08:08 | |
In this week's View, Dr. Eagle looks at how black adults in disadvantaged neighborhoods are less likely to be diagnosed with atrial fibrillation (AFib). He then examines the parameters used to detect mitral regurgitation and how they might be improved. He follows that with a look at how high coronary artery calcium scores (CAC) in young adults can signal higher 30-year mortality. Finally, Dr. Eagle offers a comparison of add-on treatments for resistant or uncontrolled hypertension (HTN). | |||
| Firefighters & Cardiac Death; HFimpEF & Sex Differences; DAPT, DOAC, and LAAO; Non-lnfarct-Related IRA & CAD | 28 Oct 2026 | 00:09:02 | |
In this week's View, Dr. Eagle looks at a brief report on how cardiac death remains a substantial contributor to on-duty mortality of U.S. firefighters, and how drivers of this trend may not be well identified by the current screening approaches. He then examines a recent article in JACC Heart Failure on how heart failure with improved ejection fraction (HFimpEF) was associated with better outcomes than persistent heart failure with reduced ejection fraction (HFrEF) in both women and men. He follows that with a look at a metanalysis that compared dual antiplatelet therapy (DAPT) and direct oral anticoagulant (DOAC) monotherapy and their effects on device-related thrombosis (DRT) and major bleeding after left atrial appendage occlusion (LAAO). Finally, Dr. Eagle offers a summary of an analysis a recent study the reported modest increase in noninfarct-related artery (non-IRA) revascularization in patients with STEMI and multivessel coronary artery disease (CAD), with some caveats. | |||
| The new ACC Scientific Statement on Exercise Prescription for CV Health, Multimodality Cardiac Imagine, Risk Stratification & CMR, Preventive PCI and CV Risk | 21 Oct 2026 | 00:11:16 | |
In this week's View, Dr. Eagle looks at the new ACC Scientific Statement on Exercise Prescriptions for Cardiovascular Health in Adults. He then examines a recent State-of-the-Art Review on the evolving role of multimodality cardiovascular imaging in the diagnosis and management of cardiac sarcoidosis (CS). He follows that with a look at a risk stratification model based on cardiac magnetic resonance (CMR) results. Finally, Dr. Eagle offers a summary of an analysis of the PREVENT trial on how preventive PCI lowers CV risk in patients with lipid-rich plaques. | |||
| Sex Disparities in CV Trials; Left Stellate Ganglion Blocks & CABG; Bifurcation Lesions; Managing Resistant Hypertension | 14 Oct 2026 | 00:08:18 | |
In this week's View, Dr. Eagle looks at continued sex disparities in CV clinical trials. He then examines how preemptive left stellate ganglion block (SGB) is associated with a reduced incidence of postoperative atrial fibrillation (POAF) in patients undergoing CABG. He follows that with a look at bifurcation lesions as analyzed in the OCTOBER Trial. Finally, Dr. Eagle offers a brief vignette on resistant hypertension and how to manage it. | |||
| ACC/AHA Joint Perioperative Guidelines; Atenolol and MACE Risk; Yoga and VPCs; DECIPHER and CMR | 07 Oct 2026 | 00:08:23 | |
In this week's View, Dr. Eagle looks at how the most recent perioperative guideline published in 2024 remains valid and current. He then examines how, in the treatment of patients without recorded heart failure (HF), starting atenolol after a myocardial infarction (MI) was associated with a lower two-year risk of major adverse cardiovascular events (MACE), but not all-cause mortality. He follows that with a look at patients with frequent ventricular premature complexes (VPCs) and how a structured yoga program compared with standard care reduced VPCs as well as improved quality of life (QOL) and psychological burden. Finally, Dr. Eagle discusses the DECIPHER HFpEF Study on cardiac magnetic resonance (CMR) tissue mapping and its capture of active relaxation impairment (σ) and passive stiffness (β) in invasively characterized heart failure with preserved ejection fraction (HFpEF). | |||
| Whole Grain Intake & CV Health, Talfamidis & Recurrent Cardiovascular Events, Revascularization & Improved Cognition, Coronary Blood Flow in Women | 30 Sep 2026 | 00:08:48 | |
In this week's View, Dr. Eagle looks at how higher whole-grain intake was associated with improvements in multiple cardiometabolic risk factors in a meta-analysis of randomized trials. He then examines how concomitant use of tafamidis or heart failure (HF) therapies did not modify the treatment benefit of vutrisiran on all-cause mortality and recurrent cardiovascular events, according to a HELIOS-B analysis, and follows that with a look in the case of patients with severe asymptomatic carotid artery stenosis, adding revascularization with either carotid artery stenting (CAS) or carotid endarterectomy (CEA) to intensive medical management (IMM) did not improve cognition compared with IMM alone, according to results from the CREST-2 randomized trials. Finally, Dr. Eagle explores how women in the CENTURY trial had higher coronary blood flow (CBF) than men while having a comparable burden of cardiovascular risk factors, similar treatment response and half the coronary events, offering a potential physiological explanation for the delayed clinical manifestation of coronary artery disease (CAD) in women. | |||
| First Medical Contact, CV Toxicity and Antibody-Drug Conjugates, Extreme Heat & Blood Pressure, FinACAF & Lower Risk of ischemic Stroke | 23 Sep 2026 | 00:10:45 | |
In this week's View, Dr. Eagle looks at a recent JACC: Advances Viewpoint that examines the challenges associated with implementing revisions to the definition of first medical contact (FMC) introduced in the 2025 ACC/AHA ACS Guideline and its implications for NCDR data collection. He then examines a cardiooncology primer on CV toxicity of antibody-drug conjugates (ADCs) in breast cancer and follows that with a look at extreme heat and blood press (BP) changes, especially among the elderly. Finally, Dr. Eagle explores the results of the FinACAF study that indicates patients with atrial flutter only (AFL-only) had a 40% lower risk of ischemic stroke than those with atrial fibrillation only (AFib-only). | |||
| CV Subspecialty Training; a Novel Left Atrium Staging Framework; the (IL)-6 Inflammatory Biomarker, HF Risk & Diabetes | 16 Sep 2026 | 00:10:41 | |
In this week's View, Dr. Eagle looks at a recent article on proposed changes to the current cardiovascular (CV) subspecialty training path. He then examines an article on a novel left atrium (LA) staging framework that stratifies new-onset atrial fibrillation risk in hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle explores the results of a Look AHEAD ancillary study on the inflammatory biomarker interleukin (IL)-6 that identified residual inflammatory risk of incident heart failure (HF) in patients with type 2 diabetes (T2D) and overweight/obesity. | |||
| Top Five Trials from ESC 26: SINGLE-AF, REBOOT-PARADOX, ViVA, REACT, NOTION-4 | 09 Sep 2026 | 00:10:52 | |
In this week's View, Dr. Eagle looks at some of the important trials presented at this year's European Society of Cardiology (ESC) Congress. First, he evaluates the SINGLE-AF trial on DOAC therapy versus no anticoagulation in atrial fibrillation (AFib) with patients with intermediate stroke risk. Dr. Eagle then examines REBOOT-PARADOX and its study of the potential value of transcatheter aortic valve replacement (TAVR) in symptomatic patients with low-flow, low-gradient aortic stenosis. Next, Dr. Eagle covers ViVA, a randomized trial that looked at vericiguat for the treatment of coronary vasospasm, followed by a summary of the REACT trial that investigated the use of imaging to detect silent atherosclerosis in early adulthood. Finally, Dr. Eagle explores NOTION-4, which looks at short-term direct oral anticoagulant (DOAC) therapy and subclinical leaflet thickening after TAVR.
| |||
| M-TEER, MR, & LV Dysfunction, Stress Perfusion CMR & CAD; Sacubutril/Valsartan, Cardiac Remodeling, and Non-Obstructive HCM. | 02 Sep 2026 | 00:07:31 | |
In this week's View, Dr. Eagle evaluates how sacubitril/valsartan promotes cardiac remodeling, but not functional capacity, in nonobstructive hypertrophic cardiomyopathy. Next, he examines the prognostic value of stress perfusion cardiac magnetic resonance in patients with suspected coronary artery disease. Finally, Dr. Eagle explores a study on mitral transcatheter edge-to-edge repair (M-TEER) and its effectiveness for treatment of patients with ventricular functional mitral regurgitation (MR) and very severe left ventricular (LV) dysfunction. | |||
| : M-TEER, MR, & LV Dysfunction, Stress Perfusion CMR & CAD; Sacubutril/Valsartan, Cardiac Remodeling, and Non-Obstructive HCM. | 02 Sep 2026 | 00:08:18 | |
In this week's View, Dr. Eagle evaluates how sacubitril/valsartan promotes cardiac remodeling, but not functional capacity, in nonobstructive hypertrophic cardiomyopathy. Next, he examines the prognostic value of stress perfusion cardiac magnetic resonance in patients with suspected coronary artery disease. Finally, Dr. Eagle explores a study on mitral transcatheter edge-to-edge repair (M-TEER) and its effectiveness for treatment of patients with ventricular functional mitral regurgitation (MR) and very severe left ventricular (LV) dysfunction. | |||
| CAC, CRF & Dementia; Athletes & Arrhythmia; Vutrisaran & Amyloid Burden; NT0proBNP Screening & Heart Failure | 26 Aug 2026 | 00:09:42 | |
In this week's View, Dr. Eagle looks at the relationship between lower cardiorespiratory fitness (CRF) and higher coronary artery calcium scores (CAC) and later-life dementia. He follows this with a look at a new State of the Art Review related to guidance on treating athletes with arrhythmia. He then offers a perspective on the use of vutrisiran in the treatment of amyloid burden. Finally, Dr. Eagle explores the TARTAN-HF study on NT-proBNP screening and its ability to identify undiagnosed heart failure (HF) among patients with diabetes. | |||
| Antithrombotic Regimens after Valve-in-Vave TAVR; TAV vs. SAVR Outcomes in Low-Risk Patients; Sex Difference and Delayed Diagnosis on Acoramidis; Lifestyle Intervention and ANOCA | 12 Aug 2026 | 00:08:35 | |
In this week's View, Dr. Eagle looks at the wide variation in antithrombotic regimens after valve-in-valve transcatheter aortic valve replacement (TAVR). Next, he examines PARTNER-3, a 7-year study on TAVR versus surgical aortic valve replacement (SAVR) outcomes in low-risk patients. He then offers a perspective on the effect of sex difference and delayed diagnosis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) from amyloidosis. Finally, Dr. Eagle explores the prospective SAMCRO trial which evaluates lifestyle intervention in addition to medical therapy in patients with invasively confirmed angina with no obstructive coronary artery disease (ANOCA).
| |||
| Venous Thromboembolism & Cancer; Influenza Vaccines & AFib; the DAPT-MVD Trial & Cutting PCI in CAD; the AC Expect Consensus Decision Pathway on HFpEF | 29 Jul 2026 | 00:09:25 | |
In this week's View, Dr. Eagle looks at a post-hoc analysis of the API-CAT trial that showed recurrent venous thromboembolism (VTE) is uncommon but associated with poor short-term survival of patients with cancer-associated thrombosis. He follows with a look at an observational cohort study on how influenza vaccination is associated with lower risks of incident atrial fibrillation (AFib), then reviews evidence from the DAPT-MVD trial demonstrating that extended DAPT lowers the risk of cardiovascular events after percutaneous coronary intervention (PCI) in multivessel coronary artery disease. Finally, Dr. Eagle explores ACC's updated expert consensus decision pathway addressing the management of heart failure preserved ejection fraction (HFpEF).
| |||
| Age, BMI, & TAVR; Enhanced Radiation Protections in Cath Labs; Particulate Matter and CV Risk; the SUMMIT Trial & Tirzepatide. | 22 Jul 2026 | 00:09:53 | |
In this week's View, Dr. Eagle looks at age, body mass index (BMI), and cardiovascular outcomes after transcatheter aortic valve replacement (TAVR). He follows this with an examination of a new consensus statement about enhanced radiation protection in cath labs, then offers a perspective on particulate matter in the environment and increased coronary heart disease risk. Finally, Dr. Eagle provides an analysis of the SUMMIT Trial, showing the benefit of tirzepatide for heart failure with preserved ejection fraction (HFpEF) both in women and men. | |||
| Mechanical Leaflet Splitting and TAVR; Ambient Temperature & Marathons; AFib, PVI with PA & IRF; the SHaRE Registry as a Predictor of MACE | 15 Jul 2026 | 00:10:12 | |
In this week's View, Dr. Eagle looks at the feasibility of mechanical leaflet splitting in high-risk patients undergoing valve-in-valve TAVR. He follows this with an examination of lower ambient temperature and it association with greater SCA risk at marathon races, then offers a commentary on two studies that provide new insights on the durability of pulmonary vein isolation (PVI) with pulsed field ablation (PA) vs radiofrequency ablation IRF) in patients with persistent atrial fibrillation (AFib). Finally, Dr. Eagle discusses the SHaRe Registry and its use in predicting major adverse cardiovascular events MACE for patients with mild hypertrophic cardiomyopathy (HCM). | |||
| Guideline-Directed Medical Therapy & Atrial Fibrillation; Anti-Platelet Therapy & ASCVD; DOACs & Prevention of Thrombotic Events; Sugar-Sweetened Beverages and Fruit Juice & Hypertension | 08 Jul 2026 | 00:09:18 | |
In this week's View, Dr. Eagle looks at withdrawing guideline-directed medical therapy (GDMT) for patients with atrial fibrillation (AF). He follows this with commentary on two important recently released ACC scientific statements: one on anti-platelet therapy for atherosclerotic cardiovascular disease (ASCVD), and the other examining the use of direct oral anticoagulants (DOACs) for primary and secondary prevention of thrombotic events. Finally, Dr. Eagle summarizes a recent longitudinal study on sugar-sweetened beverages and fruit juice and their potential relationship to the development of hypertension later in a young person's life. | |||
| Genotype and Hypertrophic Cardiomyopathy; PARTNER 2A & TAVR 10 Years Later; Clopidogrel vs. Aspirin after PCI; LDL & Risk Assessment of ASCVD | 01 Jul 2026 | 00:08:18 | |
In this week's View, Dr. Eagle looks at how genotype independently predicts heart failure outcomes in patients with hypertrophic cardiomyopathy (HCM). He then examines the ten-year follow-up of the PARTNER 2A trial and compares the transcatheter aortic valve replacement (TAVR) outcomes to results from the Partner 2 SAPIEN XT and SAPIEN 3 studies. He follows this with a report on how clopidogrel may offer a long-term edge over aspirin after percutaneous coronary intervention (PCI). Finally, Dr. Eagle summarizes HELIUS cohort findings demonstrating that LDL-C, Lp(a), and hsCRP provide complementary, independent insights for identifying long-term atherosclerotic cardiovascular disease (ASCVD) risk across diverse ethnic populations. | |||
| Lifestyle Intervention, Metformin and Multimorbidity Risk in Prediabetes; Hypertension, Hyperlipidemia and Chronic Kidney Disease, Resistance Training & Myocardial Infarction | 24 Jun 2026 | 00:09:55 | |
In this week's View, Dr. Eagle reviews 21-year follow-up data from the Diabetes Prevention Program (DPP), showing that lifestyle intervention—but not metformin—reduces multimorbidity risk in prediabetes. He also highlights low rates of hypertension and hyperlipidemia treatment among U.S. adults with cardiovascular-kidney-metabolic (CKM) syndrome, and summarizes evidence that resistance training, particularly when combined with aerobic exercise, is associated with a lower risk of cardiovascular (CV) disease, especially myocardial infarction, in women. Finally, he discusses the CAMERA-MRI II study in patients with atrial fibrillation and left ventricular systolic dysfunction (LVSD), where catheter ablation significantly improved left ventricular ejection fraction (LVEF) regardless of late gadolinium enhancement status. | |||
| Race and Sex Disparities in Mitral Valve Edge-to-Edge Repair | 17 Jun 2026 | 00:08:47 | |
In this week's View, Dr. Eagle highlights a study showing race and sex disparities in M-TEER outcomes, with Black patients presenting with more advanced disease, lower success, and higher heart failure readmissions than White patients, and women having lower success rates than men. He reviews the SOGALDI-PEF trial, where patients with low plasma renin levels experienced greater blood pressure reduction with spironolactone/dapagliflozin compared to dapagliflozin alone. Next, he discusses the FAVOR III trial, which found that QFR-guided percutaneous coronary intervention improved five-year outcomes versus angiography guidance, with most benefits occurring in the first two years. Lastly, Dr. Eagle examines two renal disease studies addressing optimal chronic kidney disease (CKD) GFR thresholds and the benefits of finerenone in CKD patients. | |||
| Impact of Semaglutide And Survival Outcomes In Patients With T2D and CKD | 10 Jun 2026 | 00:07:28 | |
In this week's View, Dr. Eagle highlights several noteworthy developments shaping cardiovascular and renal care. He first examines the FLOW analysis, underscoring the benefits of semaglutide for patients with chronic kidney disease, with particular attention to its impact on both renal and cardiovascular outcomes. He then reviews a phase I study exploring an innovative therapeutic approach involving a single intravenous infusion—Verve-2—which targets PCSK9 expression in the liver and may represent a promising future strategy for treating familial hyperlipidemia. Finally, Dr. Eagle discusses recent findings on antihypertensive drug combinations, emphasizing those regimens that provide optimal efficacy while minimizing adverse effects that often lead to early treatment discontinuation. | |||
| Postpartum Cardiovascular Care; 'Low Risk' Chest Pain in the ER; Heart Failure Risk Detection & CV Outcomes with Implantable Devices | 03 Jun 2026 | 00:09:22 | |
In this week's View, Dr. Eagle looks at recent research found in ACC's new expert decision pathway for postpartum cardiovascular care. He then offers insights from the ACC Chest Pain - MI Registry examining 'low risk' chest pain and its evaluation in the emergency departments. Next, a discussion of how negative patient outcomes were associated with late pericardial effusion post-left atrial appendage occlusion (LAAO) device implantation. Finally, Dr. Eagle summarizes the ALLEVIATE-HF trial that explored heart failure (HF) risk detection with an insertable cardiac monitor paired with a centrally coordinated nurse-led diuretic intervention. | |||
| Maintaining Weight Loss with Tirzepatide; the new Dyslipidemia Guidelines; Sacubitril/Valsartan & HFpEF & Functional MR; Digitoxin & Heart Failure | 27 May 2026 | 00:09:35 | |
In this week's View, Dr. Eagle examines recent research into maintaining weight loss with tirzepatide. He then offers insights into the new dyslipidemia guidelines, including addressing reproductive and hormone risk factors in cardiovascular risk assessment. Next, Dr. Eagle looks at the use of sacubitril/valsartan to improve exercise tolerance in patients with heart failure with reduced ejection fraction (HFpEF) and functional mitral regurgitation (MR). Finally, Dr. Eagle summarizes a new study on the use of digitoxin and digoxin in patients with heart failure. | |||
| HCM, NT-proBNP and HCM Risk Evaluation; Arrhythmic Burden in Cardiac Amyloidosis Obesity and Heart Failure; Postural Orthostatic Tachycardia Syndrome (POTS) | 20 May 2026 | 00:08:54 | |
In this week's View, Dr. Eagle reviews evidence supporting the use of cardiac magnetic resonance (CMR) and NT-proBNP in hypertrophic cardiomyopathy (HCM) risk assessment. He then examines the EXCALIBUR study, which aims to better characterize arrhythmic burden in patients with cardiac amyloidosis. Next, he discusses research identifying obesity as a significant risk factor for heart failure, highlighting key findings and clinical implications. Finally, he summarizes new evidence on the use of ivabradine and propranolol in treating postural orthostatic tachycardia syndrome (POTS). | |||
| Rhythm Control & Tricuspid Valve Regurgitation; Benefits of Blood Pressure Control on Cardiovascular Disease; Switching DOAC Therapy in AFIB Patients with Stroke; Pulsed Field Ablation & Persistent AFib | 13 May 2026 | 00:09:14 | |
In this week's View, Dr. Eagle examines the role of rhythm control in improving moderate-to-severe and severe secondary tricuspid valve regurgitation. He then explores evidence showing that blood pressure reduction can deliver comparable cardiovascular benefits for patients with chronic kidney disease (CKD). Another study reviewed in this episode assesses the outcomes of continuing versus switching direct oral anticoagulant (DOAC) therapy in patients with atrial fibrillation (AFib) who experience breakthrough stroke. Finally, Dr. Eagle summarizes the AVANTE-GUARD trial, which evaluates pulsed field ablation as a first-line treatment for patients with persistent AFib. | |||
| Pulsed Field Ablation and PAS; TRIDENT & Antihypertensive Polypharmacy; NOBLE and PCI vs. CABG | 06 May 2026 | 00:08:01 | |
In this week's View, Dr. Eagle looks at the NOBLE trial evaluating whether percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) is best for patients with unprotected left main coronary artery disease (CAD). He then explores a report highlighting nanosecond pulsed field ablation (nsPFA) and its safety and efficacy at one year for paroxysmal atrial fibrillation. Finally, Dr. Eagle presents a summary of the TRIDENT trial, which compares a triple‑pill antihypertensive strategy with conventional therapy and finds a positive impact on hypertension management and stroke risk following intracerebral hemorrhage.
| |||
| Benefits of Endovascular Therapy for Post-Thrombotic Syndrome; Sex Hormones & CV Risk; Asundexian & Stroke Risk; Cardiorespiratory Fitness & Longer Lifespans | 29 Apr 2026 | 00:09:00 | |
In this week's View, Dr. Eagle looks at endovascular therapy for post-thrombotic syndrome and how it reduces severity and improves quality of life. He then explores current evidence and strategies to address sex hormone-associated thrombotic and cardiovascular risk. Next, Dr. Eagle examines the OCEANIC-STROKE trial which studied asundexian and its potential to lower recurrent stroke risk in patients with noncardioembolic stroke or transient ischemic attack. Finally, Dr. Eagle asks the question, is high cardiorespiratory fitness associated with longer lifespan and lower multimorbidity? | |||
| Early Surgery for AS; Blood Pressure Trajectories; PCI vs Medical Therapy for Chronic Coronary Disease | 22 Apr 2026 | 00:07:40 | |
In this week's View, Dr. Eagle examines early surgery for asymptomatic patients with severe aortic stenosis. He then reviews evidence linking blood pressure trajectories and rapid control to significantly improved outcomes. Finally, he compares percutaneous coronary intervention with medical therapy for chronic total occlusion in patients with chronic coronary disease. | |||
| Caring for Patients: Cardiogenic Shock Survivorship, Masters Athletes, Medicare Spending on Semaglutide, GDMT and Veterans | 15 Apr 2026 | 00:09:06 | |
In this week's View, Dr. Eagle explores four recent articles that examine how we care for patients. First, Dr. Eagle looks at a new state-of-the-art review that outlines a multidisciplinary framework for cardiogenic shock survivorship. He then analyzes the new Joint Clinical Statement focusing on Masters athletes with abnormal cardiovascular findings, followed by details on a study of how participation in the BALANCE Model will impact Medicare spending on semaglutide. Finally, Dr. Eagle discusses how modifiable barriers may improve access to quadruple guideline-directed medical therapy for veterans with heart failure with reduced ejection fraction. | |||
| Top Takeaways from ACC.26 | 08 Apr 2026 | 00:11:23 | |
In this week's View, Dr. Eagle highlights trials from the recently held ACC Scientific Sessions which took place in New Orleans, March 28-30. Important studies discussed include:
| |||
| New ACC/AHA Dyslipidemia Guidelines Released | 18 Mar 2026 | 00:08:01 | |
In this week's View, Dr. Eagle looks at data from the STS/ACC TVT Registry on off-label transcatheter valve interventions that demonstrate reduced residual tricuspid regurgitation (TR) and improved quality of life. He then explores the REVNOVATE-COMPLEX-PCI study that investigates the benefits of intravascular imaging guidance for five years. Finally, Dr. Eagle summarizes the ACC/AHA's newly released clinical guidelines for managing dyslipidemia. | |||
| Beta-Blocker vs. Calcium-Channel Blocker in HCM | 11 Mar 2026 | 00:09:10 | |
In this week's View, Dr. Eagle looks at the differential effect of bisoprolol versus verapamil in nonobstructive hypertrophic cardiomyopathy (HCM) treatment. He then explores lower heart failure (HF) hospitalization risk in patients with type 2 diabetes, comparing GLP-1RAs to DPP-4 inhibitors and similar outcomes with SGLT-2 inhibitors. Dr. Eagle then examines the use of shared decision-making and decision aids in percutaneous left atrial appendage occlusion (LAAO). Finally, the iModern trial, which compares immediate percutaneous coronary intervention (PCI) guided by instantaneous wave-free ratio (iFR) and deferred PCI guided by cardiac stress magnetic resonance imaging (MRI) in patients with STEMI and multivessel disease, is discussed. | |||
| Increased Mortality and TAVR; Wine Intake and CV Risk; PVI & Drug-Refractory Paroxysmal Atrial Fibrillation | 04 Mar 2026 | 00:07:24 | |
In this week's View, Dr. Eagle looks at increased one-year mortality in younger patients undergoing transcatheter aortic valve replacement (TAVR). He then explores the PREDIMED trial which found that adherence to the Mediterranean diet plus moderate wine intake was associated with reduced cardiovascular risk and mortality. Finally, Dr. Eagle examines 20-year outcomes for pulmonary vein isolation (PVI) in patients with drug-refractory paroxysmal atrial fibrillation (AFib). | |||
| Self-Expanding TAVR vs Surgery; Ticagrelor vs Prasugrel in PCI; New Guidelines for Treatment of Acute Pulmonary Embolism | 24 Feb 2026 | 00:07:31 | |
In this week's View, Dr. Eagle looks at findings from the Evolut Low Risk trial in which self-expanding transcatheter aortic valve replacement (TAVR) versus surgery at six years in low-risk patients with aortic stenosis (AS) is considered. He then explores the TUXEDO-2 Trial evaluating ticagrelor versus prasugrel in percutaneous coronary intervention patients with diabetes and multivessel coronary disease (MVD). Finally, Dr. Eagle examines the first-ever release of the AHA/ACC guideline for treatment and management of acute pulmonary embolism (PE) in adults. | |||
| ORBITA-2 & PCI In Older Adults; Smartwatches and AFib Detection; Improved Management and Treatment of HF and HFrFF | 04 Feb 2026 | 00:08:19 | |
In this week's View, Dr. Eagle looks at the ORBITA-2 trial and how percutaneous coronary intervention (PCI) may lead to greater symptom relief in older adults. He then explores the EQUAL trial that investigated how Apple smartwatch monitoring improves atrial fibrillation (AFib) detection. Finally, Dr. Eagle examines revelations from the EMPEROR-Preserved trial regarding interaction between SGLT2 inhibitors and baseline magnesium levels in treating patients who have either heart failure (HF) or HF with preserved ejection fraction (HFpEF). | |||
| Exercise Testing & Systolic Blood Pressure; the Navitor TAVR valve; the ABILITY Diabetes Global Trial & Stent Comparisons for People with Diabetes | 28 Jan 2026 | 00:07:17 | |
In this week's View, Dr. Eagle looks at exercise systolic blood pressure (SBP) during stress testing related to cardiovascular (CV) events. He then explores the novel Navitor transcatheter heart valve (THV) and its safety and effectiveness in younger patients requiring transcatheter aortic valve replacement (TAVR). Finally, Dr. Eagle examines the value of 18F-FAPI PET/CT imaging and its role in assessing risk in patients with pulmonary arterial hypertension (PAH). | |||
| The State of CV Health in the US; Semaglutide and Reduced Hospital Admissions; D-Dimer and Its Use in Ruling Out DVT | 21 Jan 2026 | 00:07:19 | |
In this week's View, Dr. Eagle comments on the recently published JACC Cardiovascular (CV) Statistics report which evaluates the management of CV risk factors in the United States. He then explores the use of semaglutide and its association with reduced hospital admissions and length of stay. Finally, Dr. Eagle examines the multicenter, multinational ADJUST-DVT study on the age-adjusted use of D-dimer cut-offs for patients with suspected deep vein thrombosis. | |||
| Reducing Fat & Reducing Mortality & Stroke; Tirzepatide s. Dulaglutide; Finerenone and Hypotension; Low Operator Volume and Worse Outcomes | 14 Jan 2026 | 00:09:00 | |
In this week's View, Dr. Eagle evaluates the impacts that reducing saturated fat have on mortality, nonfatal myocardial infarction (NFMI), and stroke in high-risk individuals. He then explores the SURPASS-CVOT study which considers if tirzepatide is superior to dulaglutide in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). Next, he summarizes the FINEARTS-HF study and its investigation of finerenone and hypotension and CV outcomes according to baseline kidney function. Finally, Dr. Eagle examines how low operator volume is associated with worse transcatheter aortic valve replacement (TAVR) and mitral transcatheter edge-to-edge repair (MTEER) outcomes. | |||
| Eagle's Eye View: Top 2025 ACC Content | 07 Jan 2026 | 00:05:33 | |
In this episode, Dr. Eagle looks back at 2025 and explores some of the significant developments that show how the College is responding to changes in the way we evaluate, manage, and follow patients with various types of cardiovascular disorders. His survey of topics that received the most attention include the new guidelines on hypertension, acute coronary syndromes, the management of adults with congenital heart disease, cardiogenic shock, pericarditis, sports cardiology, weight management, amyloid heart disease and inflammation. Last year's most popular articles include insights into SGLT-2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF), flu vaccines, anticoagulation, and much more impacting the changing landscape of cardiology. | |||
| Weight Reversal Post Tirzepatide Withdrawal | 17 Dec 2025 | 00:08:11 | |
In this week's View, Dr. Eagle looks at the DANISH trial extended follow-up, evaluating which patients benefit most from primary prevention implantable cardioverter defibrillator (ICD) implantation. He then explores the SURMOUNT-4 study on weight reversal post tirzepatide withdrawal. Finally, Dr. Eagle examines two JACC articles that cover disease monitoring: one tracking the progression of transthyretin amyloid cardiomyopathy (ATTR-CM) and another assessing cardiovascular risks in patients receiving cancer therapy. | |||
| The PREVENT Equations & Cardiovascular Risk, the CREST-2 Trials on Carotid Disease , Physician Burnout, Food Labeling & CV Health | 10 Dec 2025 | 00:08:12 | |
In this week's View, Dr. Eagle looks at the use of PREVENT equations to assess cardiovascular (CV) disease risk and the CREST-2 randomized trials that examined stenting versus endarterectomy for asymptomatic carotid disease. He then explores physician burnout and the use of coaching to help treat it. Finally, Dr. Eagle explores how clearer, "front of package" food labeling in grocery stores can provide consumers with practical, science-based guidance to improve CV health.
| |||
| Improving The Culture and Climate Surrounding Cardiology | 03 Dec 2025 | 00:07:28 | |
In this week's View, Dr. Eagle looks at the potential for electrophysiology (EP) ablation in ambulatory care. He then explores several new studies that reveal the rising rates of heart failure and hypertension. Finally, Dr. Eagle discusses a very important new survey from ACC on the need to improve the professional climate and culture for US cardiologists and trainees. | |||
| Gastrointestinal Bleeding After LAAO, Lifestyle Modification & Metabolic Syndrome, Beta-Blockers & the Treatment of Preserved LVEF | 26 Nov 2025 | 00:08:35 | |
In this week's View, Dr. Eagle looks at gastrointestinal bleeding (GIB) after left atrial appendage occlusion (LAAO). He then explores lifestyle modifications to treat metabolic syndrome. Finally, Dr. Eagle examines a recent study which found that beta-blockers failed to reduce death, myocardial infarction (MI) or heart failure (HF) in patients with preserved left ventricular ejection fraction (LVEF). | |||
| Eagle's Eye View: Highlights from the 2025 AHA Scientific Sessions | 12 Nov 2025 | 00:08:31 | |
In this week's View, Dr. Eagle highlights several important studies presented at the recent American Heart Association Scientific Sessions. The OCEAN Trial on antithrombotic and stroke prevention in patients with atrial fibrillation (AFib). He then explores VESALIUS-CV, a study on evolocumab versus placebo in patients with atherosclerosis or diabetes and without previous myocardial infarction (MI) or stroke. Finally, Dr. Eagle discusses the POLY-HF study on the use of a daily polypill that boosts heart function, improves quality of life, and cuts hospitalizations in underserved patients with heart failure with reduced ejection fraction (HFrEF). | |||
| Highlights From 2025 TCT Conference | 05 Nov 2025 | 00:06:10 | |
In this week's View, Dr. Eagle highlights several trials recently presented at the TCT Conference in San Francisco. The SELUTION DeNovo trial found that use of the sirolimus-eluting balloons with bailout stenting only if necessary was noninferior to routine drug-eluting stent implantation in patients with de novo coronary artery disease. In the ANDES trial, results showed that the use of direct oral anticoagulants after left atrial appendage closure in patients with non-valvular atrial fibrillation was not superior to dual antiplatelet therapy in preventing device-related thrombosis. Finally, Dr. Eagle discusses the PROCTOR study in which percutaneous coronary intervention (PCI) on saphenous vein grafts versus native vessel PCI in post-coronary artery bypass grafting in patients presenting with graft failure.
| |||
| Aspirin, Anticoagulants, & Chronic Coronary Disease; Perioperative Blood Pressure Management; High-Dose Flu Vaccines & Hospitalizations | 29 Oct 2025 | 00:07:02 | |
In this week's View, Dr. Eagle looks at a study comparing the use of aspirin and oral anticoagulants versus anticoagulants alone in the treatment of chronic coronary disease (CCD). He then explores complications after noncardiac surgery and the efficacy of perioperative blood pressure management. Finally, Dr. Eagle discusses FLUNITY-HD, a study comparing high-dose flu vaccines to standard dose vaccines in reducing hospitalizations. | |||
| Heart Disease Mortality in California; Pregnant Women and Cardiometabolic Comorbidities; CABG and New-Onset AFib | 22 Oct 2025 | 00:07:38 | |
In this week's View, Dr. Eagle looks at the social drivers behind the rise in heart disease mortality in California. He then explores the prevalence of preexisting cardiometabolic comorbidities and cardiovascular disease among pregnant women. Finally, Dr. Eagle discusses a recent prospective cohort study of patients who undergo coronary artery bypass graft (CABG) and experience new-onset atrial fibrillation (AFib), and how the burden after surgery is very low, especially after 30 days. | |||
| Evidence and Innovations Targeting Inflammation Post-AMI | 15 Oct 2025 | 00:06:19 | |
In this week's View, Dr. Eagle looks at the potential value of sodium-glucose cotransporter 2 (SGLT2) agents after transcatheter aortic valve implantation (TAVI). He then explores a new randomized trial, HYPERION, focusing on the addition of sotatercept to lower the risk of clinical worsening in patients with pulmonary arterial hypertension (PAH). Finally, Dr. Eagle discusses a state-of-the-art review centered around the use of an anti-inflammatory to lessen cardiovascular events and worse outcomes following acute myocardial infarction (AMI). | |||
| A Look at ACC's Scientific Statement on Inflammation and CVD | 08 Oct 2025 | 00:07:07 | |
In this week's View, Dr. Eagle looks at an ACC Scientific Statement highlighting inflammation and its role in cardiovascular disease (CVD). He then explores left atrial appendage occlusion (LAAO) in patients with prior intracranial hemorrhage or ischemic stroke. Finally, Dr. Eagle discusses the recently released NEWTON-CABG CardioLink-5 trial on the use of evolocumab in the reduction of saphenous vein graft (SVG) disease rates. | |||